S'abonner

Nanoemulsion adjuvant–driven redirection of TH2 immunity inhibits allergic reactions in murine models of peanut allergy - 06/06/18

Doi : 10.1016/j.jaci.2018.01.042 
Jessica J. O'Konek, PhD , Jeffrey J. Landers, BS, Katarzyna W. Janczak, MS, Rishi R. Goel, BS, Anna M. Mondrusov, BS, Pamela T. Wong, PhD, James R. Baker, MD
 Mary H. Weiser Food Allergy Center, University of Michigan, Ann Arbor, Mich 

Corresponding authors: James R. Baker, Jr, MD, Mary H. Weiser Food Allergy Center, University of Michigan, 9220 Medical Sciences Research Building III, 1150 W Medical Center Dr, Ann Arbor, MI 48109-0648.Mary H. Weiser Food Allergy CenterUniversity of Michigan9220 Medical Sciences Research Building III1150 W Medical Center DrAnn ArborMI48109-0648Jessica J. O'Konek, PhD, Mary H. Weiser Food Allergy Center, University of Michigan, 4341 Biomedical Sciences Research Building, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200.Mary H. Weiser Food Allergy CenterUniversity of Michigan4341 Biomedical Sciences Research Building109 Zina Pitcher PlaceAnn ArborMI48109-2200

Abstract

Background

Immunotherapy for food allergies involves progressive increased exposures to food that result in desensitization to food allergens in some subjects but not tolerance to the food. Therefore new approaches to suppress allergic immunity to food are necessary. Previously, we demonstrated that intranasal immunization with a nanoemulsion (NE) adjuvant induces robust mucosal antibody and TH17-polarized immunity, as well as systemic TH1-biased cellular immunity with suppression of pre-existing TH2-biased immunity.

Objective

We hypothesized that immunization with food in conjunction with the nanoemulsion adjuvant could lead to modulation of allergic reactions in food allergy by altering pre-existing allergic immunity and enhancing mucosal immunity.

Methods

Mice were sensitized to peanut with aluminum hydroxide or cholera toxin. The animals were then administered 3 monthly intranasal immunizations with peanut in the nanoemulsion adjuvant or saline. Mice were then challenged with peanut to examine allergen reactivity.

Results

The NE intranasal immunizations resulted in marked decreases in TH2 cytokine, IgG1, and IgE levels, whereas TH1 and mucosal TH17 immune responses were increased. After allergen challenge, these mice showed significant reductions in allergic hypersensitivity. Additionally, the NE immunizations significantly increased antigen-specific IL-10 production and regulatory T-cell counts, and the protection induced by NE was dependent in part on IL-10. Control animals immunized with intranasal peanut in saline had no modulation of their allergic response.

Conclusions

NE adjuvant–mediated induction of mucosal TH17 and systemic TH1-biased immunity can suppress TH2-mediated allergy through multiple mechanisms and protect against anaphylaxis. These results suggest the potential therapeutic utility of this approach in the setting of food allergy.

Le texte complet de cet article est disponible en PDF.

Key words : Food allergy, peanut allergy, nanoemulsion, adjuvant, intranasal immunization, allergen immunotherapy, allergic disease

Abbreviations used : alum, BAL, CTx, Foxp3, MCPT-1, mLN, NE, Treg


Plan


 This project has been funded by United States Department of Defense Award W81XWH-14-PRMRP-DA, a Food Allergy Research & Education New Investigator Award, and a generous gift from the Shaevsky family.
 Disclosure of potential conflict of interest: J. J. O'Konek has received grants from Food Allergy Research & Education (FARE), the United States Department of Defense, and the Shaevsky Family and has a patent pending (PCT/US2015/054943). J. J. Landers, K. W. Janczak, R. R. Goel, A. M. Mondrusov, and P. T. Wong have received grants from FARE, the United States Department of Defense, and the Shaevsky Family. J. R. Baker, Jr, has received grants from the United States Department of Defense and the Shaevsky Family; is CEO and CMO of FARE; has a patent pending (PCT/US2015/054943); and is a stockholder in a company that has licensed this patent.


© 2018  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 141 - N° 6

P. 2121-2131 - juin 2018 Retour au numéro
Article précédent Article précédent
  • Single-cell profiling of peanut-responsive T cells in patients with peanut allergy reveals heterogeneous effector TH2 subsets
  • David Chiang, Xintong Chen, Stacie M. Jones, Robert A. Wood, Scott H. Sicherer, A. Wesley Burks, Donald Y.M. Leung, Charuta Agashe, Alexander Grishin, Peter Dawson, Wendy F. Davidson, Leah Newman, Robert Sebra, Miriam Merad, Hugh A. Sampson, Bojan Losic, M. Cecilia Berin
| Article suivant Article suivant
  • MicroRNA-4443 regulates mast cell activation by T cell–derived microvesicles
  • Irit Shefler, Pazit Salamon, Francesca Levi-Schaffer, Adam Mor, Alon Y. Hershko, Yoseph A. Mekori

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.